United StatesHealth

Oculis Holding AG (NASDAQ:OCS) shares climbed today after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Privosegtor (OCS-05), a first-in-class neuroprotective candidate for the treatment of optic neuritis.

The designation, announced January 6, 2026, marks a major milestone for the Swiss biotech as it targets a $7 billion U.S. market for optic neuropathies.

Natera (NASDAQ:NTRA) announced a significant clinical breakthrough today, revealing that its pivotal Phase III ALTAIR trial successfully reached statistical significance following a reclassification of patient data.

The Trump administration is rolling back federal child care funding rules as officials cite fraud concerns and freeze payments.

US regulators have cut the list of vaccines routinely recommended for all children, citing international comparisons and public trust concerns.

Moderna (NASDAQ:MRNA) officially moved to challenge the multi-billion-dollar seasonal influenza market today, submitting marketing authorization applications for its investigational vaccine, mRNA-1010, to regulators in the U.S., Europe, Canada, and Australia.

Zenas BioPharma (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused on developing transformative immunology-based therapies for autoimmune diseases, today announced positive topline results from the Phase 3 INDIGO registrational trial evaluating obexelimab in patients with Immunoglobulin G4-Related Disease (IgG4-RD).

Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric disorders and neurodegenerative diseases, today reported positive topline results from a Phase 1b signal-seeking study evaluating NMRA-511 as a potential treatment for agitation in patients with Alzheimer's disease.

RedHill Biopharma (NASDAQ:RDHL) is positioning its proprietary oral drug, RHB-102 (Bekinda), as a critical solution to the "discontinuation crisis" facing the blockbuster weight-loss drug market.

Gyre Therapeutics (NASDAQ:GYRE) is moving toward a landmark commercial entry in China after securing alignment with the Center for Drug Evaluation (CDE) on a conditional approval pathway for its lead anti-fibrotic candidate, Hydronidone (F351).

GH Research (NASDAQ:GHRS) shares surged in early trading Monday after the U.S. Food and Drug Administration lifted a long-standing clinical hold on its Investigational New Drug (IND) application for GH001.

Argenx SE (NASDAQ:ARGX) announced a significant leadership transition on Monday, appointing Chief Operating Officer Karen Massey as its new Chief Executive Officer and Executive Director, effective immediately.

HUTCHMED (NASDAQ:HCM) announced today that it has initiated the Phase III stage of its ongoing Phase II/III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine (S+C+AG) as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in China.